MAGI-1b Inhibitors
MAGI-1b inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the MAGI-1b protein, a member of the membrane-associated guanylate kinase with inverted domain structure (MAGI) family. MAGI-1b is a scaffolding protein involved in assembling protein complexes at specialized cellular junctions, such as tight junctions and adherens junctions. These structures are critical for maintaining cell-cell adhesion and cellular polarity, which are important for various cellular processes, including tissue organization, signaling pathways, and the maintenance of the epithelial barrier. MAGI-1b facilitates interactions between membrane-bound proteins and cytoplasmic signaling molecules, contributing to the regulation of intracellular signaling, especially pathways that control cellular structure and communication. By inhibiting MAGI-1b, researchers can investigate its role in these processes and how it influences cellular organization and signaling networks.
In research settings, MAGI-1b inhibitors are valuable tools for studying the molecular mechanisms by which MAGI-1b regulates cell junctions and signaling pathways. By blocking MAGI-1b activity, scientists can explore the downstream effects on cell polarity, adhesion, and the integrity of cellular barriers. This inhibition allows researchers to assess how the disruption of MAGI-1b-mediated interactions impacts cellular communication and structural stability, particularly within tissues that rely on tight junctions, such as epithelial layers. Additionally, MAGI-1b inhibitors help uncover the protein's role in larger signaling networks, including its interactions with other proteins that contribute to cellular growth, differentiation, and signaling cascades. Through these studies, the use of MAGI-1b inhibitors provides a deeper understanding of the importance of scaffolding proteins in maintaining cellular architecture and regulating complex intracellular communication systems.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may downregulate MAGI-1b expression by halting mTORC1 signaling, a pathway that controls the translation of proteins including those involved in cell growth and proliferation, potentially reducing the synthesis levels of MAGI-1b. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 could decrease MAGI-1b expression by inhibiting PI3K activity, causing a reduction in AKT phosphorylation and subsequent transcriptional activity of genes controlled by this pathway, which may include MAGI-1b. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
As a pyrimidine analog, Fluorouracil may decrease MAGI-1b expression by disrupting the synthesis of pyrimidine nucleotides, leading to a reduction in RNA transcription and subsequent protein synthesis, potentially including the biosynthesis of MAGI-1b. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol may downregulate MAGI-1b expression through its action on sirtuin pathways that control the transcription of certain genes. This downregulation could occur if MAGI-1b expression is linked to the deacetylation events influenced by sirtuins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 has the potential to reduce MAGI-1b expression by blocking p38 MAP kinase activity, which may be involved in the cellular stress response that includes the transcriptional control of genes such as MAGI-1b. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin may downregulate MAGI-1b expression by interacting with transcription factors that specifically bind to the promoter regions of genes like MAGI-1b, thereby decreasing their transcriptional activity and thus the expression of MAGI-1b. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib may inhibit the expression of MAGI-1b by preventing the degradation of ubiquitinated proteins, thereby causing a buildup of these proteins that could lead to altered gene expression. If MAGI-1b turnover is regulated by ubiquitination, bortezomib might reduce its expression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine could downregulate MAGI-1b expression by hypomethylating DNA and activating the expression of genes involved in tumor suppression. If MAGI-1b is typically suppressed by methylation, decitabine could lead to reduced MAGI-1b expression. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide may reduce MAGI-1b expression by altering the transcription of genes through its interaction with the E3 ubiquitin ligase complex. If MAGI-1b expression is regulated by proteins that are modulated by thalidomide, its expression could be diminished. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib has the potential to decrease MAGI-1b expression by inhibiting multiple tyrosine kinases. If these kinases are involved in signaling pathways that control the transcription of MAGI-1b, sorafenib could lead to a reduction in its expression levels. | ||||||